CPHI & P-MEC China explores emerging trends in biopharm and pharma packaging
New regulations speeding up growth with exports to Japan targeted.
CPHI and P-MEC China – hosted by UBM EMEA and CCCMHPIE and co-organized by UBM Sinoexpo – announce the major trends emerging from the recent closing of its 2016 exhibition at Shanghai New International Expo Center. The biggest ever pharma event in Asia welcomed 32,646 visitors from over 120 countries and 2,737 exhibitors, ensuring that a diverse range of exhibitors and visitors came together as a community to share their expertise.
At CPHI and P-MEC China pharma professionals engaged in deep discussions on the exciting innovations revolutionizing the regional industry and its vast export potential. China is making strides to be the most innovative player in the pharma value chain, and foreign investors are increasingly targeting the country, adding to the considerable domestic investment already available.
To augment domestic growth, the government has focused on reforming the pharmaceutical approval system, with efforts to clear the drug application backlog under way. These changes will increase administrative efficiency and give Chinese pharma companies a competitive advantage in the global market.
During the International Summit for Pharmaceutical Packaging and Drug Delivery Systems, it was predicted that the packaging sector would have an average growth rate of roughly 10% per annum for the next few years, and it is becoming an increasingly lucrative market in the Chinese economy.
Another trend to emerge from the exhibition is the rapid development of the biopharmaceutical sector in the country. Seminars examined issues such as ‘Challenges and Opportunities for the R&D of Biosimilars’, which covered the difficulties, quality, and learning applications of biosimilars. Already the largest producer of pharma ingredients globally – 82% of China’s exports are bulk ingredients – China has plans to establish itself as a competitive player in the biomedical drug trade. The session on ‘How to improve the quality and yield of the materials in the sterile production’ provided essential insights for China’s early stage biologics community who are now looking to scale up their operations.
Finally, many Chinese companies are also exploring exporting high-value APIs in new markets, with Japan as primary target, and CPHI China featured the China-Japan Pharmaceutical Industrial Symposium, which included sessions on ‘trading problems and solutions for APIs’, and ‘Japanese market entry strategies’.
In 2016, CPHI and P-MEC China added 10,000 additional square metres of floor space, increasing the total exhibition area to 160,000 square metres. Growth from the 2015 exhibition and conference numbers demonstrates the parallel growth of the Chinese economy. Overall, the programme included contributions from 182 speakers, 50 seminars, 24 forums, and two C-level networking events.
Domestic biopharmaceutical giants such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shenzhen Mellow Hope and Dongcheng Biochemicals, along with international CROs like Wuxi Apptec, ChemPartner, Asychem, and Chiral Quest all attended the event to push forward Chinese pharma growth.
“We are delighted with the success and record-breaking turnout of the 16th edition of CPHI China, as well as being a hub of new business and partnerships, it is also a key event to monitor the latest trends across this dynamic pharma manufacturing region and economy. By bringing together this many executives and pharma supply companies we are actively helping drive forward innovation. Each year new audiences and exhibitors attend the exhibition with biopharmaceutical, pharma machinery, natural extracts, packaging companies and CROs adding to the over 1000+ pharma ingredient suppliers. Over the next few years we anticipate the increased internationalization of this event,” said Chris Kilbee Brand Director Pharma at UBM EMEA.
Related News
-
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News CPHI Frankfurt 2022: Innovator Interviews – Bioiberica
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We caught up with Mónica Gómez Navarro (Marketing Manager Branded Ingredients), ... -
News CPHI Frankfurt 2022: Innovator Interview – Procaps Group
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We interviewed Rosella Del Vecchio Herrera, Marketing Director at Procaps Group, to discover h... -
News From the floor - CPHI Frankfurt 2022
The live blog from the people on the ground at CPHI Frankfurt - covering all stand-out news, memorable moments, and keynote updates from the 2022 event. -
News How to Commercialise an Advanced Therapy: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Andrea Zobel, Senior Director, Personalized Supply Chain at World Courier (Berlin Germany), Melissa Lattanzi, VP Emerging Therapies at AmerisourceBergen (King of Prussia, USA), and Hans-Peter Scherzer, Customer Suc... -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance